• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Ryan J. Sullivan, MD


  • Sullivan RJ, Fisher DE.Understanding the Biology of Melanoma and Therapeutic Implications.Hematol Oncol Clin North Am. 2014 Jun;28(3):437-453.
  • Luo X, Mitra D, Sullivan RJ, Wittner BS, Kimura AM, Pan S, Hoang MP, Brannigan BW, Lawrence DP, Flaherty KT, Sequist LV, McMahon M, Bosenberg MW, Stott SL, Ting DT, Ramaswamy S, Toner M, Fisher DE, Maheswaran S, Haber DA.Isolation and Molecular Characterization of Circulating Melanoma Cells.Cell Rep. 2014 Apr 16.
  • Ackerman A, Klein O, McDermott DF, Wang W, Ibrahim N, Lawrence DP, Gunturi A, Flaherty KT, Hodi FS, Kefford R, Menzies AM, Atkins MB, Long GV, Sullivan RJ.Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors.Cancer. 2014 Feb 27.
  • Wagle N, Van Allen EM, Treacy DJ, Frederick DT, Cooper ZA, Taylor-Weiner A, Rosenberg M, Goetz EM, Sullivan RJ, Farlow DN, Friedrich DC, Anderka K, Perrin D, Johannessen CM, McKenna A, Cibulskis K, Kryukov G, Hodis E, Lawrence DP, Fisher S, Getz G, Gabriel SB, Carter SL, Flaherty KT, Wargo JA, Garraway LA.MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.Cancer Discovery. 2014 Jan;4(1):61-8.
  • Panka DJ, Mier JW, Sullivan RJ.Assaying for BRAF V600E in tissue and blood in melanoma.Methods Mol Biol. 2014;1102:117-36.
  • Sullivan RJ, Atkins MB.Emerging clinical issues in melanoma in the molecularly targeted era.Methods Mol Biol. 2014;1102:11-26.
  • Cooper ZA, Frederick DT, Juneja VR, Sullivan RJ, Lawrence DP, Piris A, Sharpe AH, Fisher DE, Flaherty KT, Wargo JA.BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes.Oncoimmunology. 2013 Oct 1;2(10):e26615.
  • Luke JJ, Callahan MK, Postow MA, Romano E, Ramaiya N, Bluth M, Giobbie-Hurder A, Lawrence DP, Ibrahim N, Ott PA, Flaherty KT, Sullivan RJ, Harding JJ, D'Angelo S, Dickson M, Schwartz GK, Chapman PB, Wolchok JD, Hodi FS, Carvajal RD.Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience.Cancer. 2013 Oct 15;119(20):3687-95.
  • Sullivan RJ, Lorusso PM, Flaherty KT.The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: where we have been, are, and will be.Clin Cancer Res. 2013 Oct 1;19(19):5283-91.
  • Sullivan RJ, Lawrence DP, Wargo JA, Oh KS, Gonzalez RG, Piris A.Case records of the Massachusetts General Hospital. Case 21-2013. A 68-year-old man with metastatic melanoma.N Engl J Med. 2013 Jul 11;369(2):173-83.
  • Postow MA, Luke JJ, Bluth MJ, Ramaiya N, Panageas KS, Lawrence DP, Ibrahim N, Flaherty KT, Sullivan RJ, Ott PA, Callahan MK, Harding JJ, D'Angelo SP, Dickson MA, Schwartz GK, Chapman PB, Gnjatic S, Wolchok JD, Hodi FS, Carvajal RD.Ipilimumab for patients with advanced mucosal melanoma.Oncologist. 2013 Jun;18(6):726-32.
  • Sullivan RJ, Flaherty KT.Resistance to BRAF-targeted therapy in melanoma.Eur J Cancer. 2013 Apr;49(6):1297-304.
  • Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, Ferrone CR, Mitra D, Boni A, Newton LP, Liu C, Peng W, Sullivan RJ, Lawrence DP, Hodi FS, Overwijk WW, LizĂ©e G, Murphy GF, Hwu P, Flaherty KT, Fisher DE, Wargo JA.BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.Clin Cancer Res. 2013 Mar 1;19(5):1225-31.
  • Joseph RW, Eckel-Passow JE, Sharma R, Liu P, Parker A, Jakob J, Buchbinder E, Bassett RL, Davies MA, Hwu P, Atkins MB, Sullivan RJ.Characterizing the Clinical Benefit of Ipilimumab in Patients Who Progressed on High-dose IL-2.J Immunother. 2012 Nov;35(9):711-715.
  • Sullivan RJ, Pantanowitz L.New drug targets in Kaposi sarcoma.Expert Opin Ther Targets. 2010 Dec;14(12):1355-66.
  • Frankenthaler A, Sullivan RJ, Wang W, Renzi S, Seery V, Lee MY, Atkins MB.Impact of concomitant immunosuppression on the presentation and prognosis of patients with melanoma.Melanoma Res. 2010 Dec;20(6):496-500.
  • Sullivan RJ, Atkins MB.Molecular targeted therapy for patients with melanoma: the promise of MAPK pathway inhibition and beyond.Expert Opin Investig Drugs. 2010 Oct;19(10):1205-16.
  • Panka DJ, Sullivan RJ, Mier JW.An inexpensive, specific and highly sensitive protocol to detect the BrafV600E mutation in melanoma tumor biopsies and blood.Melanoma Res. 2010 Oct;20(5):401-7.
  • Sullivan RJ, Atkins MB.Cytokine therapy in melanoma.J Cutan Pathol. 2010 Apr;37 Suppl 1:60-7. Review.
  • Sullivan RJ, Pantanowitz L, Dezube BJ.Studying Rac1-induced tumorigenesis suggests antioxidants may help prevent and treat Kaposi's sarcoma.Future Oncol. 2009 Sep;5(7):949-52.
  • Sullivan RJ,Atkins MB.Molecular-targeted therapy in malignant melanoma.Expert Rev Anticancer Ther. 2009 May;9(5):567-81. Review.
  • Sullivan RJ,Pantanowitz L,Casper C,Stebbing J,Dezube BJ.HIV/AIDS: epidemiology, pathophysiology, and treatment of Kaposi sarcoma-associated herpesvirus disease: Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman disease.Clin Infect Dis. 2008 Nov 1;47(9):1209-15. Review.